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ABSTRACT 20 
Chemotherapy-induced gastrointestinal (GI) toxicity is a common adverse effect of cancer treatment. 21 
We used preweaned piglets as models to test our hypothesis that the immunomodulatory and 22 
gastrointestinal trophic effects of bovine colostrum would reduce the severity of GI complications 23 
associated with doxorubicin treatment. Five-day-old pigs were administered doxorubicin (DOX, 1 x 24 
100 mg/m2) or an equivalent volume of saline (SAL) and either fed formula (DOX-Form, n=9 or SAL-25 
Form, n=7) or bovine colostrum (DOX-Colos, n=9 or SAL-Colos, n=7). Pigs were euthanized five 26 
days after initiation of chemotherapy to assess markers of small intestinal function and inflammation. 27 
All DOX-treated animals developed diarrhea, growth deficits and leukopenia. However, the intestines 28 
of DOX-Colos pigs had lower intestinal permeability, longer intestinal villi with higher activities of 29 
brush border enzymes, and lower tissue IL-8 levels compared with DOX-Form (all P<0.05). DOX-30 
Form pigs, but not DOX-Colos pigs, had significantly higher plasma C-reactive protein (CRP), 31 
compared with SAL-Form. Plasma citrulline was not affected by DOX treatment or diet. Thus, a single 32 
dose of doxorubicin induces intestinal toxicity in preweaned pigs and may lead to a systemic 33 
inflammatory response. The toxicity is affected by type of enteral nutrition with more pronounced GI 34 
toxicity when formula is fed compared with bovine colostrum. The results indicate that bovine 35 
colostrum may be a beneficial supplementary diet for children subjected to chemotherapy and 36 
subsequent intestinal toxicity. 37 
 38 
Keywords: Chemotherapy-induced mucositis, intestinal toxicity, enteral nutrition, milk, bovine 39 
colostrum 40 
41 
3 
 
NEW AND NOTEWORTHY 42 
In this study, pre-weaned pigs were used as models to study intestinal complications after doxorubicin 43 
as models for pediatric oncology patients receiving chemotherapy. This study shows that the type of 44 
enteral nutrition is an important factor that can influence the toxic responses related to doxorubicin 45 
treatment. Compared with formula, bovine colostrum nutrition provided beneficial effects against the 46 
intestinal injury which occurred early after doxorubicin administration.   47 
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INTRODUCTION 48 
Gastrointestinal (GI) toxicity is a major dose-limiting adverse effect of chemotherapy with 49 
implications for both morbidity and mortality (11, 48). The associated symptoms include pain, nausea, 50 
vomiting, and diarrhea affect nutritional status and quality of life. These complications are related to 51 
adverse clinical outcomes, prolonged hospitalization and need for parenteral nutrition. Due to mucosal 52 
barrier injury there are increased risks of fever and infections, potentially leading to increasing 53 
mortality (11, 18, 48, 53). Emerging clinical strategies for GI toxicity, including drugs, probiotics and 54 
nutritional interventions (3, 28, 65) have not been effective and GI dysfunction often hinders adequate 55 
enteral nutrition support which provides energy, macronutrients and dietary bioactive factors (37, 63). 56 
Enteral nutrition may therefore help to reduce inflammatory conditions in the GI tract (1) and this 57 
could be important in association with chemotherapy.  58 
While the survival of childhood cancer has improved over the last decades it is still the leading 59 
cause of disease-related mortality in children (62). The improved survival is partly related to intensified 60 
and risk-stratified chemotherapy regimens which have led to increased toxicity, underlining the need 61 
for better understanding and management of treatment-related complications in these patients. At the 62 
forefront is chemotherapy-induced intestinal dysfunction. The associated malnutrition and toxic 63 
complications may lead to dose reduction or treatment delays, compromising treatment efficacy.  64 
Nutrition could be particularly important for outcome in pediatric cancer patients that are still a state of 65 
growth and organ maturation (4, 8). Studies also suggest that cancer and chemotherapy in infancy and 66 
early childhood can be more challenging to manage and may have worse outcomes compared with 67 
older children (40, 42, 62), potentially due to immaturity of organs such as the GI tract. Knowledge 68 
about this patient group is limited and comparable pediatric animal models for chemotherapy-induced 69 
mucositis are relevant to provide new basic knowledge. Until now, such models have focused mainly 70 
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on rodents (33) but their physiology differ markedly from humans, and their small size and immature 71 
state at birth limit their use as a translational model for infants and young children, compared with a 72 
species like the pig (39, 51). The larger size of preweaned and juvenile pigs also make it easier to use 73 
standard clinical and medical care procedures when inducing and evaluating chemotherapy toxicity (35, 74 
36, 45, 46, 59).  75 
Bovine colostrum contains many bioactive compounds, such as immunoglobulin (Ig), 76 
transforming growth factor β (TGF-β) and insulin-like growth factor 1 (IGF-1) that may stimulate gut 77 
growth and function and provide mucosal protection via immunomodulatory effects and changes to the 78 
gut microbiota (44). Thus, colostrum may promote GI mucosal protection via antimicrobial and 79 
endotoxin-neutralizing effects, suppression of gut inflammation, and by facilitating mucosal tissue 80 
repair. In preterm pigs, enteral feeding with bovine colostrum protects against necrotizing enterocolitis 81 
(NEC), a severe condition with inflammatory and ulcerative lesions in the GI tract (24). Thus, bovine 82 
colostrum might provide gastrointestinal and systemic benefits in several disease states involving 83 
damage to the GI mucosa (44).  84 
Recent studies have used preweaned and weaned pigs as models for chemotherapy-induced 85 
intestinal toxicity (36, 45) and these may provide animal models to study liquid diet interventions 86 
during a period of rapid growth and development, similar to pediatric patients. Liquid milk-based diets 87 
are highly digestible and easy to adjust in nutrient composition and intake for chemotherapy patients 88 
requiring tube feeding. In this study, we hypothesized that GI toxicity after treatment of preweaned 89 
pigs with doxorubicin (DOX) would be reduced by feeding bovine colostrum compared with a standard 90 
formula diet. Doxorubicin (DOX) is an anthracycline which causes DNA intercalation and is 91 
commonly used in many anticancer regimens, with multiple organ toxicities, including 92 
myelosuppression, cardiotoxicity, and GI toxicity (5, 7, 64).  93 
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 94 
MATERIAL AND METHODS 95 
Animals, surgical preparation, clinical procedures and chemotherapy 96 
All animal procedures were approved by the Danish National Committee on Animal 97 
Experimentation (no. 2010/561-1760).  An overview of the experimental approach is shown in Fig. 1. 98 
A total of 32 pigs (Large White × Danish Landrace) of both sexes were obtained on the third day of life 99 
after having suckled their mother from birth.  The pigs were brought to the research facilities where 100 
they were housed in individual cages in a facility kept at a constant temperature (~30⁰ C) with a 12 h 101 
light/12 h dark cycle.  Each cage contained behavioral enrichments (toy-cloths) and allowed visual 102 
contact among individual pigs.  103 
Shortly after arrival, the pigs were anesthetized using zoletil mix (i.m. tiletamine, 0.28 mg/kg; 104 
zolazepam, 0.28 mg/kg; xylazine, 0.56 mg/kg; ketamine, 0.56 mg/kg; butorphanol, 0.11 mg/kg) for 105 
placement of  an orogastric feeding tube (6F Portex, Kent, UK) that was inserted through the cheek and 106 
secured with sutures. A catheter (Tygon OD 0.070 ID 0.040 Saint-Gobain Performance Plastics, France) 107 
was surgically inserted into the external jugular vein, tunneled under the skin and exteriorized through 108 
the dorsal part of the neck and used for blood sampling and administration of DOX. The pigs were fed 109 
either bovine colostrum (Colos) or formula (Form) and within each diet group pigs received DOX 110 
chemotherapy or saline (SAL), with a randomized block design resulting in four groups with similar 111 
distribution of initial body weight, sex and litter of origin: DOX treated animals fed bovine colostrum 112 
(DOX-Colos, n = 9) or formula (DOX-Form, n = 9), and saline groups fed bovine colostrum (SAL-113 
Colos, n = 7) or formula (SAL-Form, n = 7).  The pigs were fed every 3 h by placing 15 mL/kg of their 114 
respective diet in a feeding trough. Voluntary food intake was allowed, but if appetite was reduced any 115 
remaining feed was fed through the orogastric tube. The composition of the Form diet was based on 116 
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commercially available clinical nutrition products, i.e. Pepdite (60 g/L, powdered enteral nutrition with 117 
non-milk derived low molecular weight peptides, essential amino acids, carbohydrate, fat, vitamins, 118 
and minerals, Nutricia, Allerød, Denmark), Lacprodan (50 g/L, whey protein, Arla Foods Ingredients, 119 
Aarhus, Denmark),  Miprodan (50 g/L, casein, Arla Foods Ingredients), Calogen (50 g/L, long chain 120 
triglyceride fat emulsion, Nutricia), Liquigen (80 g/L, medium chain triglyceride from fractionated 121 
coconut oil, Nutricia) and Seravit-SHS (12 g/L, vitamins and trace elements Nutricia).  The 122 
macronutrient composition in the Form diet was 5291 kJ/L (energy), 96 g/L (protein), 40 g/L 123 
(carbohydrate, with 36 g/L maltodextrins) and 79 g/L (fat). The colostrum was collected from Danish 124 
dairy cows within 24 h of parturition, pooled and spray-dried to a powder and γ-irradiated to eliminate 125 
microorganisms (Biofiber-Damino, Gesten, Denmark). The Colos powder was reconstituted in water 126 
(200 g/L) and yielded macronutrient values of 3986 KJ/L (energy), 94 g/L (protein, with 28 g/L IgG), 127 
36 g/L (carbohydrate), and 48 g/L (fat).  128 
 129 
Chemotherapy 130 
Two days after the surgery and the start of the respective feeding regimens the pigs were 131 
administered a single intravenous (i.v.) dose of DOX over 30 min, corresponding to 100 mg/m2 body 132 
surface area or an equivalent volume of SAL. This dose of DOX is comparable with doses used in 133 
treatment of pediatric cancers such as acute lymphoblastic leukemia (ALL) and has been shown to 134 
induce intestinal toxicity in weaned pigs (36). Body surface area was calculated as 70 × kg body weight 135 
0.75 /1000 (9), providing approximately 5-5.5 mg/kg DOX for the 2.5-3.5 kg pigs. 136 
 137 
Clinical assessment 138 
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Animals were monitored for clinical status including daily measurements of body weight, 139 
temperature, and diarrhea scoring. Diarrhea was assessed by visually categorizing waste collection 140 
trays below the cages and animal staining, providing a daily score of 0 (no stools or normal stools), 1 141 
(mild diarrhea), or 2 (severe diarrhea). Humane endpoints for euthanasia of animals prior to d 5 were as 142 
described elsewhere (46). 143 
 144 
Hematology, CRP, and in vivo markers of intestinal function 145 
Blood samples were collected at baseline, immediately prior to administration of DOX, on d 3 146 
and on d 5 (the time of euthanasia) for hematology and analyses of C-reactive protein (CRP) and 147 
citrulline. Hematological parameters included red blood cell (RBC), white blood cells (WBC), 148 
neutrophils (NEU), lymphocytes (LYM), and platelet (PLT) count (Advia 2120 Hematology System, 149 
Siemens, Erlangen, Germany). These parameters have previously been shown to correlate with toxicity 150 
in pigs (46). Circulating CRP is a marker of systemic inflammatory response commonly used to 151 
indicate inflammation and infection in both humans and pigs and was measured with an enzyme-linked 152 
immunosorbent assay (ELISA) using a validated method for pigs (21). Plasma citrulline is synthesized 153 
by enterocytes and is considered a marker for intestinal mass and function, as well as a marker of 154 
damage after chemotherapy (60). For detection of citrulline (17), analytes extracted from serum 155 
samples were separated and detected by ultra-performance liquid chromatography- triple quadrupole 156 
mass spectrometry (Waters, Milford, MA, USA). Quantification of citrulline was carried out using an 157 
analysing software, QuanLynx (Waters). 158 
At baseline and again on day 4, the pigs were fed one bolus (15 mL/kg) of a 10% lactose 159 
solution via the feeding tubes to assess the capacity for lactose digestion as a marker for intestinal 160 
function. The bolus was given 3 h after the last feed instead of the normal diet. Blood samples were 161 
9 
 
collected 20 min after the bolus and plasma galactose levels were measured spectrophotometrically 162 
(Pentra 400, Horiba ABX, Montpellier, France) using a commercial kit (55). Before sacrifice on d 5, 163 
animals received a bolus (15 mL/kg) of 5% lactulose and 5% mannitol solution via the feeding tube 3 h 164 
after the previous meal to assess intestinal permeability. A urine sample was collected by cystocentesis 165 
during necropsy 3-5 h after the lac/man-bolus. Urinary concentrations of lactulose and mannitol were 166 
determined spectrophotometrically (Pentra 400) and intestinal permeability was assessed by the ratio of 167 
lactulose to mannitol (lac/man ratio).  168 
 169 
Necropsy and tissue collection 170 
On d 5, the pigs were anesthetized using the zoletil mix before intracardial collection of a blood 171 
sample after which the pigs were euthanized by intracardial injection of sodium pentobarbital, 200 172 
mg/kg. After death was confirmed, the abdomen was opened and the small intestine (from the pyloric 173 
sphincter to the ileo-cecal junction) was removed quickly, placed on a cooled surface and divided into 174 
three segments of equal length, designated proximal (Prox), middle (Mid), and distal (Dist) intestine, 175 
respectively. For each segment, two pieces of ~0.5 cm were collected and fixed in 4% neutral buffered 176 
formalin. After fixation, samples were dehydrated with ethanol, embedded in paraffin and cross-177 
sectioned (5 µm), mounted on glass slides, and stained with hematoxylin and eosin. Additional tissue 178 
samples from each intestinal region were snap-frozen in liquid nitrogen for subsequent analyses. 179 
Finally, a 10 cm piece of each region was collected for determining the proportional weight of mucosa, 180 
relative to whole intestine.  The remaining organs were collected and their weights recorded.   181 
  182 
Intestinal tissue structure, brush border enzymes and proinflammatory cytokines 183 
10 
 
Villus height and crypt depth were determined as previously described (46). The proportion of 184 
the small intestine represented by mucosa was determined by scraping off the mucosal layer and drying 185 
(49). The frozen intestinal samples were processed for analyses of brush border enzymes and cytokine 186 
levels as described elsewhere (46, 50). Briefly, the tissues were homogenized  in 1%  Triton X-100 and 187 
the activities of three dissacharidases (lactase, maltase, sucrase) and three peptidases (aminopeptidase 188 
A, ApA; aminopeptidase N, ApN; dipeptidylpeptidase IV, DPP-IV) were expressed as a hydrolytic rate 189 
of 1 µmol substrate released per min at 37 oC per g wet whole intestinal tissue. Intestinal inflammatory 190 
responses were based on cytokine levels in the Dist region, and measured using the DuoSet ELISA 191 
Development kit (R&D Systems, Abingdon, UK) targeted for porcine interleukin-1β (IL-1b), 192 
interleukin-6 (IL-6), interleukin 8 (IL-8), and tumor necrosis factor α (TNF-α), according to the 193 
manufacturer’s instructions. 194 
 195 
Intestinal proliferation, apoptosis, and structural proteins.  196 
Enterocyte proliferation was assessed by immunohistochemistry, staining for Ki-67 on sections 197 
from the Mid intestine, as described previously (58). Quantification was performed by image analysis 198 
using Visiomorph 4.6  (Visiopharm, Copenhagen). The total area of Ki 67-positive stained nuclei were 199 
calculated and presented as a fraction of all nuclei. 200 
Expression of PCNA was used as a marker of proliferation and that of Caspase-3 as a marker of 201 
apoptosis. β-actin and GAPDH proteins were quantified by Western blot and uused as indicators of 202 
basic cytostructural and metabolic conditions, as previously described (25). Briefly, 25 mg protein 203 
extracted from the mid intestine segments was resolved by electrophoresis and transferred onto PVDF 204 
membranes. The expression of PCNA, caspase-3 and β-actin were shown with specific antibodies 205 
(Santa Cruz, CA, USA, and Abcam, Cambridge, UK). The protein bands on the membranes were 206 
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visualized and the band densities were detected by Image J (NIH, MD, USA). Protein loading was 207 
controlled by direct staining of the electrophoresis gels run parallel to the ones for Western blot, using 208 
methods described previously (20). 209 
 210 
Statistical analyses 211 
Statistical analyses were performed with the statistical software R (version 2.15.0). Weight gain 212 
was expressed as the percentage change in weight, relative to the start of DOX administration. 213 
Continuous data were analyzed using mixed models (lmer function) with the groups as independent 214 
variables and with adjustments for sex, baseline body weight, and study round (3 rounds of pig studies 215 
with evenly distributed groups and genders) as explanatory variables. For repeated measures analyses, 216 
the individual pig-identifier was included in the model as a random effect. Normality was assessed by 217 
means of standardized residuals and log-transformed to account for variance heterogeneity, when 218 
necessary. Adjustments for baseline values were included in the model for longitudinal data. Group 219 
comparisons were done with the lsmeans package with multiplicity adjustments of P-values with the 220 
single-step method. For sample values lower than assay detection limit, these were assigned the lowest 221 
value of the assay range. Diarrhea score was analyzed as nonparametric data with the nparcomp 222 
package. P-values <0.05 were considered significant. Graphs were made with GraphPad Prism (version 223 
5.01; GraphPad Software, La Jolla, CA, USA). Data are presented as arithmetic mean and SEM of raw 224 
data unless otherwise specified.  225 
 226 
RESULTS 227 
Clinical status and growth 228 
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All pigs continued to eat and remained active and clinically stable during the 5 d study period.  229 
No pigs required euthanasia according to humane endpoints prior to the end of the protocol. All of the 230 
pigs gained weight between d 0, when DOX (or saline) was administered, and d 2 (Fig. 2A). After d 3, 231 
weight gain decreased for both groups of DOX pigs, resulting in stable body weight of DOX-Colos 232 
pigs from d 3-5 and weight reduction for DOX-Form pigs. The two groups of SAL pigs continued to 233 
gain weight until d 5. Growth on d 5 was significantly lower in DOX-Form pigs, compared with both 234 
groups of SAL pigs (P < 0.05, Fig. 2A), whereas weight for DOX-Colos pigs was not different from 235 
that in SAL pigs. Initial weight gain (d 0-2) tended to be greater for both groups of Form pigs, 236 
compared with Colos pigs (Fig. 2A). Diarrhea was commonly observed from d 3 after DOX 237 
administration with increasing severity thereafter (Fig. 2B). Diarrhea scores were similar in DOX-Form 238 
and DOX-Colos pigs. However, DOX-Form pigs had higher diarrhea score than SAL groups on d 3 239 
and d 4 whereas scores in DOX-Colos were not significantly elevated until d 4, relative to SAL pigs 240 
(Fig. 2B). Diarrhea in SAL pigs was restricted to one mild transient case at the start of the study period. 241 
Vomiting was observed in one DOX-Form pig on d 4 and d 5. No effects on appetite or food intake 242 
were observed.  243 
 244 
Blood hematology and systemic inflammatory response 245 
Administration of DOX reduced WBC, compared with SAL on d 3 and 5 (P < 0.05, Fig. 3A). 246 
DOX also reduced LYM values on both days, whereas NEU were not affected, and no diet effect was 247 
detected for WBC, LYM or NEU (Fig. 3A-C). On d 5, PLT values were lower in DOX versus SAL 248 
pigs, as analyzed for each of the diet regimens (P < 0.05, Fig. 3D), with no differences between DOX-249 
Colos and DOX-Form. RBC did not differ among groups (Fig. 3E). Longitudinal measurements of 250 
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CRP did not differ significantly among groups on d 0 and d 3. However, on d 5 levels were higher for 251 
DOX-Form pigs, compared with DOX-Colos and SAL-Form pigs (P<0.05, Fig. 3F).  252 
 253 
 254 
Gut function markers in vivo 255 
After two days of Form or Colos feeding, and before the DOX (or saline) was administered, 256 
plasma galactose measured 20 min after a lactose bolus was lower for Form than for Colos pigs (92 ± 257 
12 versus 200 ± 26 µmol/L, respectively, P<0.01). On d 4, galactose values were similar for both 258 
groups of Colos pigs, and both were higher than for the two groups of Form pigs, regardless of SAL or 259 
DOX administration (pooled means ± SEM: 36.2 ± 9.7 versus 4.4 ± 3.4 µmol/L, respectively, P < 0.05), 260 
indicating that diet, but not DOX treatment, affected galactose uptake capacity. Among the groups, 261 
mean gut permeability, as assessed by the lac/man-ratio, was lowest for DOX-Colos pigs (P < 0.05 262 
compared with DOX Form, Fig. 4A). Plasma citrulline did not differ significantly among groups, 263 
regardless of diet or whether DOX was administered.  264 
 265 
Intestinal and inflammatory responses 266 
Macroscopic signs of GI mucosal damage were not observed in any of the groups and only one 267 
pig from the DOX-Form group had signs of edema in the colon. Only among the Form pigs, did DOX 268 
treatment reduce small intestinal weight (-38%, P < 0.05), with less (non-significant) effects of DOX 269 
within the Colos pigs (Table 1). The percentage of intestinal weight represented by mucosa was 270 
significantly reduced in DOX-Form pigs, but not in DOX-Colos pigs, both compared to their respective 271 
saline controls (P < 0.05, Fig. 4B). Analyzed across the two diets, the DOX treatment decreased 272 
intestinal weight and colon weight compared with SAL (P < 0.05), but when analyzed for each diet 273 
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separately, only the DOX-induced reduction in intestinal weight in formula-fed piglets was significant 274 
(30% reduction, P < 0.05, Table 1). For the weight of other internal organs, the spleen was most 275 
affected by DOX with a reduction to 30-50%, compared with SAL (P < 0.05), with no effect of diet 276 
(Table 1). Across SAL and DOX treatments, liver weight was significantly lower in Colos pigs 277 
compared with Form (P < 0.05, Table 1). 278 
 DOX-Colos pigs had the longest villi in the middle and distal intestinal regions compared with 279 
DOX-Form and SAL-Colos (P<0.05, Fig. 5A). The DOX treatment reduced crypt depths across all 280 
three regions and across diets, indicating lowered crypt cell proliferation (P < 0.05 for Colos and trend 281 
for Form, Fig. 5B). Consequently, the villus to crypt ratios in the middle and distal regions were 282 
increased in the DOX-Colos group, compared with all the other groups (P < 0.05, Fig. 5C).  283 
Disaccharidase activities were highest in Prox and Mid intestinal regions, while peptidase 284 
activities were highest in Mid and Dist regions (Fig. 5D-I). Only for Colos pigs were the lactase, 285 
sucrase and maltase activities higher for DOX versus SAL pigs (P < 0.05, Fig. 5D-F). No significant 286 
DOX effect was detected for Form pigs. Similarly, it was only for Colos pigs that DPP-IV activity was 287 
higher for DOX versus SAL pigs (Fig. 5G). Concentrations of the proinflammatory cytokines, IL-8 and 288 
IL-6 (Fig. 6) were lower in the Dist intestine of pigs fed colostrum (P < 0.05 across treatments), but 289 
only for IL-8 were values for DOX-Colos lower than for DOX-Form pigs (P < 0.05, Fig. 6A). Tissue 290 
levels of IL-1β and TNF-α did not differ between diets and treatments. 291 
 292 
Proliferation, apoptosis and intracellular structure  293 
Immunohistochemistry staining of Ki-67 positive cells in the intestine showed lower number of 294 
cells in DOX-Colos pigs compared with SAL-Colos pigs (P<0.05), and numbers were similar to those 295 
in the DOX-Form and SAL-Form pigs which showed no differences (Fig. 7A, G). Yet, there was a 296 
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significant negative effect of chemotherapy on Ki-67 positive cells when analyzed across diets 297 
(P<0.001). Western blot of PCNA revealed similar results in that values were lower in DOX-Colos 298 
than in SAL-Colos pigs (P<0.05), while DOX-Form tended to show lower values than SAL-Form pigs 299 
(P=0.19, Fig 7D), with no significant effects of diet. Cleaved caspase-3 values were significantly lower 300 
in DOX-Form than in the other three groups which had similar levels (P<0.05 Fig. 7B). Uncleaved 301 
Caspase-3 did not differ significantly among groups (Fig. 7E), although DOX increased the values, 302 
relative to SAL, as analyzed across diets (P<0.01). Overall, DOX treatment decreased the β-actin and 303 
GAPDH levels, with limited effects of diet, Fig. 7C and 7F).  304 
 305 
DISCUSSION 306 
Nutritional support is critical during treatment of pediatric cancer patients to prevent 307 
malnutrition which decreases chemotherapy tolerance, increases toxicity and infection rates, and 308 
compromises outcome (4). Enteral nutrition formulas are preferred over total parenteral nutrition 309 
because of assumed benefits for the gut (37) and are recommended in patients with a functional 310 
gastrointestinal tract.  Yet, there is no consensus regarding the type of enteral nutrition support for 311 
pediatric patients. Our findings indicate that the type of liquid diet support influences the response to 312 
the chemotherapeutic agent, doxorubicin, and that a diet rich in milk bioactive factors, such as bovine 313 
colostrum, might be beneficial.   314 
In humans, gut toxicity develops early after chemotherapy (27) and the onset of diarrhea and 315 
weight loss 3-4 days after treatment in the current study coincides with the onset of GI toxicity in older, 316 
weanling piglets after a single dose of doxorubicin (36). Likewise, the intestinal structural response to 317 
DOX (e.g. decreased intestinal weight and amount of mucosa) is consistent with data from studies in 318 
juvenile pigs (36). On the other hand, the administration of DOX did not significantly change lactose 319 
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digestive capacity, gut permeability and tissue proinflammatory cytokines and possibly some intestinal 320 
responses to DOX are less pronounced in preweaned versus weaned juvenile pigs, at least on day 5 321 
after treatment. This may be explained by a more immature inflammatory response during early life, 322 
compared with adult patients, despite that a gut inflammatory response is thought to be a central 323 
element in the complications of chemotherapy across all patients (19, 26). Regardless, it is important to 324 
note that the present results of DOX are documented in a state of early intestinal development and 325 
effects on a more mature intestine could be different. CRP is a systemic marker of inflammatory and 326 
infectious complications (38) and the elevated CRP levels in this study are consistent with a systemic 327 
inflammatory response after DOX treatment. Likewise, the markedly reduced spleen weight and 328 
changes in hematology after a single dose of DOX were consistent with reduced hematopoiesis.  329 
Growing children and their GI tract are highly responsive to the type of nutrition support (6, 55). 330 
In addition to macronutrients, bovine colostrum contains numerous bioactive compounds that influence 331 
both gut maturation and systemic immunity. This includes GI growth, digestive function, mucosal 332 
immune function and inflammation, and the resident microbiota. These may have contributed to the 333 
different responses of the SAL pigs fed colostrum, compared with those fed formula. Nevertheless, the 334 
colostrum diet fed to piglets not exposed to DOX was associated with slower body weight gain, 335 
compared with pigs fed formula, and colostrum did not in this study increase the length and weight of 336 
the small intestine, villus height, crypt depth, or activity of digestive enzymes in the SAL pigs. 337 
Potentially, the most beneficial effects of colostral bioactive factors are restricted to the immediate 338 
neonatal period, consistent with the lacking effect of bovine colostrum on intestinal nutrient function in 339 
healthy adults or stable short bowel syndrome patients (12, 34, 47). Nevertheless, the observed 340 
increases in lactose digestive capacity and reduced permeability in colostrum-fed SAL pigs may 341 
suggest some intestinal benefits, relative to formula. These differences could also be related to potential 342 
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direct negative effects of the chosen formula diet. In preterm pigs, detrimental effects on gut structure 343 
and function have been induced by formulas very similar to the one used in this study (43, 55) and the 344 
damaging effects were at least partly related to replacing milk lactose with maltodextrins (56). Such 345 
formulas only cause severe intestinal inflammation and pathology in preterm pigs, not in normal term 346 
pigs, although some intestinal functions may be negatively affected also in term pigs (55).  347 
Bioactive factors in milk have previously been reported to ameliorate mucosal toxicity after 348 
administering chemotherapeutic agents to rats and hamsters and there is also some evidence for 349 
beneficial effects in human chemotherapy patients (10, 13, 15, 22, 23, 44, 57). Such effects include 350 
reducing bacterial translocation across the gut mucosa in patients after abdominal surgery (14) and 351 
reducing intestinal permeability caused by non-steroidal anti-inflammatory drugs that facilitate 352 
bacterial translocation to the mesenteric lymph nodes, liver, spleen, and peripheral blood (29, 30). The 353 
different intestinal and systemic responses between DOX pigs fed colostrum or formula suggests that 354 
bovine colostrum may be particularly beneficial during inflammatory processes. This is consistent with 355 
the beneficial colostrum effects observed for inflammatory conditions in humans (44, 47, 52) and for 356 
the devastating GI inflammatory disease in preterm infants, necrotizing enterocolitis (24, 41, 54). 357 
The greater mucosa proportion, villus height, lactose digestive capacity and reduced 358 
permeability in the DOX pigs fed colostrum, relative to formula, highlight the benefits of bovine 359 
colostrum on gut structure and function during DOX chemotherapy. This is corroborated by lowered 360 
IL-8 in ileal tissue and lower circulating CRP levels, and is consistent with other results from pigs (36, 361 
46). The higher activities of the measured brush border enzymes and increased villus length, 362 
particularly in the DOX-Colos pigs, may indicate that colostrum stimulated intestinal regeneration after 363 
chemotherapy. Regardless, Ki-67 and PCNA analyses did not show signs of increased intestinal 364 
proliferation on day 5 after DOX treatment, suggesting that most of the colostrum-stimulated adaptive 365 
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proliferation had already occurred by this time point. In line with this, other experimental studies have 366 
demonstrated a very early onset of cellular toxicity after DOX treatment and that intestinal responses 367 
are highly dynamic with cellular regeneration within few days of DOX administration (16, 61). 368 
Interestingly, we found very low levels of Cleaved Caspase-3 in the DOX-Form group, the group with 369 
the worst clinical outcome, while DOX-Colos pigs had similar levels as saline controls. This suggests 370 
that the Caspase-3 pathway is not dominating the DOX-related cell death, at least not 5 d after DOX 371 
treatment similar to findings in other studies (16, 31). The reduced level of cleaved Caspase-3 in DOX-372 
Form is even more evident when adjusted relative to the level of uncleaved Caspase-3. This indicates 373 
that Caspase-3 activation  is somehow affected (66). The accumulation of uncleaved Caspase-3 in the 374 
DOX groups could indicate altered expression as a response to chemotherapy. Conversely, there was a 375 
more consistent negative effect of DOX on β-actin and GAPDH protein abundance, reflecting that 376 
chemotherapy affected structural and metabolic processes of the intestinal cells (2, 32), even 5 d after 377 
treatment. These two proteins are normally considered high-abundance housekeeping proteins with 378 
fundamental functions for most cells and are often used for protein loading control when analyzing 379 
Western blots (2, 32). Such cellular protein controls are therefore negatively affected and therefore 380 
unreliable in studies of chemotherapy-induced mucositis, as also indicated in other studies (2, 32).  381 
We have demonstrated that preweaned pigs provide a good model for studying the responses to 382 
chemotherapeutic agents during early life and for evaluating liquid diets for enteral nutrition support to 383 
address the associated toxicity and GI disturbance. Although the incidence of cancer is low among 384 
infants, the unique nature of the immature intestine and the responses to chemotherapy need to be 385 
better understood for more effective chemotherapy in this sensitive population. A limitation of our 386 
study is the use of only a single dose of doxorubicin. Chemotherapeutic regimens typically involve 387 
multiple rounds of treatment which combined with other drugs increases the toxicities. Questions 388 
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remain regarding the more long-term outcomes in both animals and children (35, 59) and whether 389 
colostrum would shorten the recovery period, allowing for more frequent chemotherapy.  390 
The findings indicate that bovine colostrum or other bioactive milk products may be beneficial 391 
to include into the enteral nutrition support during chemotherapy. DOX had more severe effects on GI 392 
parameters in Form-fed compared with Colos-fed pigs, illustrating that the intestinal response to 393 
chemotherapy is diet-dependent. However, the colostrum diet was associated with relatively low body 394 
weight gains, even in control pigs, and it might be suboptimal and also unfeasible to supply bovine 395 
colostrum as the sole source of enteral nutrition for pediatric cancer patients for extended periods. Still, 396 
the present study highlights how nutritional intervention may reduce toxic responses to DOX in piglets, 397 
and consequently, we have initiated a clinical study on bovine colostrum as a diet supplement to 398 
children with leukemia receiving chemotherapy (ClinicalTrials.gov Identifier: NCT01766804).    399 
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FIGURE CAPTIONS 609 
Fig. 1. Study design with enteral nutrition intervention using formula (Form) or bovine colostrum 610 
(Colos). Catheters and feeding tubes were fitted surgically two days prior to chemotherapy. 611 
Doxorubicin (DOX) or saline (SAL) was administered on d 0. Blood samples were collected prior to 612 
the treatment, d 3 and 5, and analyzed for hematologic parameters and C-reactive protein. Digestive 613 
capacity of lactose was tested on d 4 and intestinal permeability was assessed with the 614 
lactulose/mannitol-test (lac/man test) on d 5 when animals were sacrificed. Doxorubicin-treated pigs 615 
fed formula (DOX-Form, n = 9), saline-treated pigs fed formula (SAL-Form, n = 7), doxorubicin-616 
treated pigs fed bovine colostrum fed (DOX-Colos, n = 9), and saline-treated pigs fed bovine colostrum 617 
(SAL-Colos, n = 7).  618 
 619 
Fig. 2. Weight gain (A) indicated as percent change relative to initial body weight prior to treatment on 620 
d 0 and diarrhea score (B) presented as mean ± SEM. Doxorubicin-treated pigs fed formula (DOX-621 
Form, n = 9), saline-treated pigs fed formula (SAL-Form, n = 7), doxorubicin-treated pigs fed bovine 622 
colostrum (DOX-Colos, n = 9), and saline-treated pigs fed bovine colostrum (SAL-Colos, n = 7). 623 
Different superscript letters indicate significant differences among groups within the same time point 624 
(P < 0.05). 625 
 626 
Fig. 3. Circulating levels of white blood cells (WBC, A), neutrophils (NEU, B), lymphocytes (LYM, 627 
C), platelets (PLT, D), red blood cells (RBC, E) and C-reactive protein (CRP, F) presented as means ± 628 
SEM. Doxorubicin-treated pigs fed formula (DOX-Form, n = 4-9), saline-treated pigs fed formula 629 
(SAL-Form, n = 4-7), doxorubicin-treated pigs fed bovine colostrum (DOX-Colos, n = 4-9), and saline-630 
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treated pigs fed bovine colostrum (SAL-Colos, n = 2-7). Different superscript letters indicate 631 
significant differences among groups within the same time point (P < 0.05). 632 
 633 
Fig. 4. Intestinal permeability (A) measured on d 5 as the urinary ratio of lactulose to mannitol 3-5 h 634 
after an enteral bolus of lactulose and mannitol solution and proportion of mucosal mass relative to 635 
total intestinal mass (B) presented as means ± SEM. Doxorubicin-treated pigs fed formula (DOX-Form, 636 
n = 4-9), saline-treated pigs fed formula (SAL-Form, n = 7), doxorubicin-treated pigs fed bovine 637 
colostrum (DOX-Colos, n = 8-9), and saline-treated pigs fed bovine colostrum (SAL-Colos, n = 7). 638 
Different superscript letters indicate significant differences among groups within the same time point 639 
(P < 0.05).  640 
 641 
Fig. 5. Villus height (A), crypt depth (B), villus-crypt ratio (VC-ratio, C), and activity of lactase (D), 642 
sucrase (E), maltase (F), DPP-IV (G), ApA (H), and ApN (I) measured in the proximal (Prox), middle 643 
(Mid), and distal (Dist) regions of the small intestine, respectively (mean ± SEM). Doxorubicin-treated 644 
pigs fed formula (DOX-Form, n = 9), saline-treated pigs fed formula (SAL-Form, n = 7), doxorubicin-645 
treated pigs fed bovine colostrum (DOX-Colos, n = 9), and saline-treated pigs fed bovine colostrum 646 
(SAL-Colos, n = 7). Different superscript letters indicate significant differences among the four groups 647 
within the same region (P < 0.05). 648 
 649 
Fig. 6. Tissue levels of proinflammatory cytokines interleukin-8 (IL-8, A) and interleukin-6 (IL-6, B) 650 
in the distal region of the small intestine (mean ± SEM). Doxorubicin-treated pigs fed formula (DOX-651 
Form, n = 9), saline-treated pigs fed formula (SAL-Form, n = 7), doxorubicin-treated pigs fed bovine 652 
29 
 
colostrum (DOX-Colos, n = 9), and saline-treated pigs fed bovine colostrum (SAL-Colos, n = 7). 653 
Different superscript letters indicate significant differences among the four groups (P < 0.05). 654 
 655 
Fig. 7. Markers of proliferation, apoptosis, and intracellular structure. Immunohistochemistry staining 656 
and analysis of Ki-67 (A, G) and Western blot quantification of PCNA (D), Cleaved Caspase-3 (B), 657 
Caspase-3 (E), β-actin (C), and GAPDH (F) in intestinal tissue samples from the middle region (mean 658 
± SEM). Doxorubicin-treated pigs fed formula (DOX-Form, n = 9), saline-treated pigs fed formula 659 
(SAL-Form, n = 6-7), doxorubicin-treated pigs fed bovine colostrum (DOX-Colos, n = 8-9), and saline-660 
treated pigs fed bovine colostrum (SAL-Colos, n = 6-7). Different superscript letters indicate 661 
significant differences among the four groups (P < 0.05). 662 
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 Table 1. Organ weights at necropsy 
 Form  Colos  
 SAL  DOX  SAL  DOX  
     
Stomach 7.3 ± 0.9  7.7 ± 0.7   7.5 ± 0.6  8.3 ± 0.7   
Intestine  43.8 ± 1.7 b  30.2 ± 2.3 a  37.5 ± 1.2 ab  33.2 ± 2.1 a  
Colon 12.1 ± 0.7 ab  11.1 ± 1.6 a  14.8 ± 1.3 b  12.0 ± 0.7 ab  
Liver 35.6 ± 2.0  36.0 ± 1.0  32.3 ± 0.8  32.4 ± 0.8  
Lungs 19.4 ± 1.8  15.7 ± 1.3  19.5 ± 3.0  19.8 ± 1.6  
Heart 7.8 ± 0.4  7.4 ± 0.5  7.6 ± 0.1  7.2 ± 0.4  
Spleen 3.8 ± 0.5 b  1.3 ± 0.2 a  4.1 ± 0.3 b  2.0 ± 0.2 a  
Kidneys 9.5 ± 0.7  9.1 ± 0.5  9.0 ± 0.5  8.8 ± 0.4  
         
Organ weights expressed relative to body weight (g/kg, mean ± SEM).  Doxorubicin-treated pigs 
fed formula (DOX-Form, n = 9), saline-treated pigs fed formula (SAL-Form, n = 7), doxorubicin-
treated pigs fed bovine colostrum (DOX-Colos, n = 9), and saline-treated pigs fed bovine colostrum 
(SAL-Colos, n = 7). Different superscript letters indicate significant differences among the four 
groups (P < 0.05).  
